[Back to Contents Page]

 

Current Medicinal Chemistry–Immunology, Endocrine & Metabolic Agents Volume 4, No. 4, 2004

 

Contents

 

Imaging Diabetic Pancreas

Guest Editor: Anna Moore

 

Why Image the Pancreatic Beta Cell? Pp.251-252

Maren R. Laughlin

[Abstract]

 

Optical Imaging Agents and Potential Application in the Assessment of Pancreatic Beta Cells Pp.253-269

Samuel Achilefu

[Abstract]

 

Potential Approaches for Beta Cell Imaging with PET and SPECT Pp.271-280

C.-Y. Shiue, A. Schmitz, R. Schirrmacher, G. G. Shiue and A. Alavi

[Abstract]

 

Imaging of Pancreatic Beta-Cell Signal-Transduction Pp.281-299

Martin Kohler, Daniel Nyqvist, Tilo Moede, Helene Wahlstedt,Over Cabrera, Ingo Leibiger and Per-Olof Berggren

[Abstract]

 

Bioluminescence Imaging of Pancreatic Islet Transplants Pp.301-308

Xiaojuan Chen and Dixon B. Kaufman

[Abstract]

 

Antibodies to Islet Beta Cell Surface Markers Pp.309-313

Ole D. Madsen and Klaus H. Kaestner

[Abstract]

 

Approaches for Imaging the Diabetic Pancreas: First Results Pp.315-331

Anna Moore and Zdravka Medarova

[Abstract]

 

Imaging Metabolic and Signaling Targets in the Pancreatic Beta Cell Pp.333-337

Louis H. Philipson and Michael Wm. Roe

[Abstract]

 

In Vivo Bioluminescence Imaging to Assess Pancreatic Islets Pp.339-347

Alvin C. Powers and E. Duco Jansen

[Abstract]

 

Toward the Design of MR Agents for Imaging b-Cell Function Pp.349-369

Mark Woods, Shanrong Zhang and A. Dean Sherry

[Abstract]

 

Abstracts

 

[Back to top] Why Image the Pancreatic Beta Cell?

Maren R. Laughlin

 

 

[Back to top] Optical Imaging Agents and Potential Application in the Assessment of Pancreatic Beta Cells

Samuel Achilefu

 

Diseases of the pancreas are life-threatening because of its central role in glucose homeostasis and digestion. Regulation of blood glucose falls within the purview of pancreatic beta cells, whose primary role is to produce insulin. Malfunctioning of beta cells can lead to diabetes, the severity of which has been shown to correlate with pancreatic beta cell mass (PBCM). Consequently, methods that can image PBCM would play a major role in the management of type 1 diabetes. To be successful, such imaging methods must be highly sensitive and specific because of the anatomical challenges and the small size of the pancreas. The desired sensitivity and specificity can be obtained in conjunction with molecular contrast effectors to decipher pathologic from normal tissues. Because of its high sensitivity, nuclear methods have been the dominant molecular imaging method for human applications. For this reason, a variety of radiopharmaceuticals has been developed. To minimize the exposure of patients to radioactivity, optical imaging is a complementary and viable alternative to nuclear methods. Optical methods are highly sensitive and use non-ionizing radiation to interrogate the molecular basis of pathogenesis. This review will focus on the development of molecular beacons and their potential application in the imaging of pancreatic beta cells. It is most likely that contrast-mediated optical imaging of pancreatic islet cells will combine molecular specificity with high sensitivity to furnish useful diagnostic and prognostic information by endoscopic methods. Alternatively, minimally invasive continuous organ function monitoring methods could be developed to assess indirectly the functional status of pancreatic beta cells by optical spectroscopy.

 

[Back to top] Potential Approaches for Beta Cell Imaging with PET and SPECT

C.-Y. Shiue, A. Schmitz, R. Schirrmacher, G. G. Shiue and A. Alavi

 

Diabetes mellitus is a major public health problem and comprises a heterogeneous group of disorders characterized by high blood glucose levels. Two major types of diabetes mellitus have been defined: type 1 and type 2. Pancreatic beta-cell mass (BCM) is markedly reduced in type 1 diabetes due to selective autoimmune destruction of insulin-producing beta-cells of the pancreas. To date, the accurate assessment of pancreatic beta-cells in human diabetes has been limited to autopsy studies, which usually suffer from inadequate clinical information. Thus, the development of noninvasive technique to assess the state of viability of beta-cells in vivo during the silent phase of prediabetes or after islet transplantation will be useful for clinical intervention. A number of imaging modalities have been proposed to evaluate BCM including cellular imaging, MRI, and nuclear imaging. However, none of these modalities has yet been successfully applied to human studies. In this article, we review the development and the feasibility of using radiolabeled metals, monoclonal antibody, monosaccharides, sulfonylurea receptor ligands and gene expression reporter probes as radiotracers for imaging BCM with PET and SPECT.

 

[Back to top] Imaging of Pancreatic Beta-Cell Signal-Transduction

Martin Kohler, Daniel Nyqvist, Tilo Moede, Helene Wahlstedt,Over Cabrera, Ingo Leibiger and Per-Olof Berggren

 

The development of techniques that enable the characterization of critical parameters of pancreatic b-cell function in a non-invasive manner is of immense value in diabetes research. These techniques will not only allow a better understanding of b-cell physiology and dysfunction, but will be of practical help in the evaluation of islet material used for transplantation into type 1 diabetic patients. In the present review we discuss approaches, e.g. probes and microscopy/digital imaging techniques, which are used to evaluate parameters reflecting the b-cell’s potential to convert the blood glucose concentration signal into an appropriate secretory response of insulin. These parameters include measurements of changes in the concentration of ATP, the formation of NAD(P)H, changes in the mitochondrial membrane potential DYm, changes in cytoplasmic pH, as well as changes in cytoplasmic free [Ca2+]. Moreover, we present techniques that permit online monitoring of gene expression in living b-cells and online detection of apoptosis of these cells. Finally, we discuss strategies that will allow the analysis of b-cell stimulus-secretion coupling under in vivo conditions. This includes monitoring of b-cell function in their ‘natural setting’, i.e. the pancreas, as well as the analysis of  b-cells within grafts following transplantation.

 

[Back to top] Bioluminescence Imaging of Pancreatic Islet Transplants

Xiaojuan Chen and Dixon B. Kaufman

 

Bioluminescence imaging (BLI) modalities have been developed, refined, and used broadly in the study of small animal models of human biology and disease. Here, we review the importance of developing an in vivo imaging modality for real-time monitoring islets post transplantation. In order to advance our understanding of the pathophysiology and immunobiology of islet transplantation as they occur in living animals, islet grafts tagged with lightemitting luciferase can be implanted in a mouse islet transplantation model and assessed using in vivo BLI. Some of the preliminary data, considerations of using the system, and future applications of BLI in the field of islet transplantation research are discussed.

 

[Back to top] Antibodies to Islet Beta Cell Surface Markers

Ole D. Madsen and Klaus H. Kaestner

 

Insufficient functional beta cell mass is a common denominator in most forms of diabetes. It will be important to be able to image the functional beta cell mass during onset and/or progression of type 1 and type 2 diabetes. It would be equally useful to possibly image beta-cell neo-formation. With the establishment of the Beta Cell Biology Consortium (BCBC) and its core facilities, one goal is to generate antibody tools against stage specific surface markers characterizing the sequential maturation from pancreatic precursors to mature beta-cells. We believe that such antibodies will also be useful for imaging the corresponding stages. Several BCBC research groups, as well as the Antibody and the Functional Genomics Cores, are involved in this project. Here we outline the overall approaches and strategies employed by the BCBC. An ultimate goal for the Consortium is that such antibody tools will allow for the optimization of in vitro culture conditions that will replicate normal pancreatic beta-cell ontogeny – a prerequisite for generating clinically relevant betacell mass for diabetes therapy.

 

[Back to top] Approaches for Imaging the Diabetic Pancreas: First Results

Anna Moore and Zdravka Medarova

 

Non-invasive imaging of the diabetic pancreas is a long sought goal of clinical investigators. Challenges remain in imaging the diabetic pancreas and studies on pancreatic tissues are generally limited to autopsy. This review focuses on the new, fast developing field of molecular imaging of the diabetic condition both in Type I and Type II diabetes. The major areas under study include approaches to the measurement of beta-cell mass (BCM), early detection of lymphocyte infiltration in pancreatic islets during autoimmune attack and methods for visualizing beta-cell apoptosis occurring in Type I and Type II diabetes mellitus. In spite of being only a few years old, this new field has shown significant progress in developing methods to study BCM, lymphocyte invasion and its consequences in animal models. The results of these and other studies will be ultimately used for devising therapeutic interventions, monitoring their efficacy, as well as imaging high-risk patients. We expect that these methods will give us the ability to detect and, possibly, follow the early progression of diabetes, which will greatly aid and simplify the pharmacological intervention of this disease.

 

[Back to top] Imaging Metabolic and Signaling Targets in the Pancreatic Beta Cell

Louis H. Philipson and Michael Wm. Roe

 

New methods are needed to image specific molecules, cells and cellular processes to better understand insulin secretion from islets of Langerhans in situ, the defects that occur in diabetes mellitus, and the results of b-cell replacement therapy. These methods are critical to further our understanding of the biogenesis and adaptive responses of insulinsecreting cells. Imaging techniques for these applications can be considered from those that resolve from the nano- scale to several centimeters, with time resolutions that might range from milliseconds to years. Static structural imaging may be helpful in estimating b-cell mass, but this should be complemented by functional approaches to understand the secretion defects that may be seen in diabetes. In this brief review we discuss potential targets for functional imaging of b-cells in vitro and in vivo.

 

[Back to top] In Vivo Bioluminescence Imaging to Assess Pancreatic Islets

Alvin C. Powers and E. Duco Jansen

 

Secretion of insulin by pancreatic islets is crucial for glucose homeostasis; disorders in islet function contribute to all types of diabetes mellitus. Transplantation of pancreatic islets into the liver is an emerging therapy for type 1 diabetes. However, limitations in assessing the number or mass of islets in vivo greatly hinder efforts to understand islet physiology and pathophysiology and to develop new therapies. Pancreatic islet size (50-200 mM), location (scattered throughout pancreas or liver after transplantation), and mass (only 1-2% of pancreatic mass and < 1% of liver mass after transplanted into the liver) create formidable challenges to non-invasively assess islet mass. One molecular imaging modality being adapted to non-invasively assess islet mass is in vivo bioluminescence imaging (BLI). BLI refers to the quantification of photons emitted from luciferase-expressing cells after luciferin administration using a sensitive chargecoupled device. This review summarizes approaches to use BLI to non-invasively assess murine and human islets after transplantation into immunodeficient mice. The ability to sequentially assess islet mass in vivo should allow investigators to investigate the events after islet transplantation and to develop interventions to improve islet survival.

 

[Back to top] Toward the Design of MR Agents for Imaging b-Cell Function

Mark Woods, Shanrong Zhang and A. Dean Sherry

 

The chemistry of Gd3+-based MRI agents has advanced considerably during the past decade toward agents with higher relaxivity and agents that respond to physiology and/or metabolism. This review describes various approaches that have been taken toward the development of responsive contrast agents and discusses the importance of fast water exchange for advancement of targeted Gd3+-based agents with higher sensitivity. The recent discovery of Eu3+ complexes having extraordinarily slow water exchange has opened a new avenue in contrast agent design based upon the chemical exchange saturation transfer (CEST) mechanism. These new paramagnetic complexes called PARACEST agents offer new possibilities of imaging biological functions such as tissue pH and metabolite levels. The lower detection limits that may apply to each class of contrast agent (Gd3+-based versus PARACEST) are discussed and the extent to which they may be applied to the imaging of b-cells is considered.